# EDGAR Filing Document

**Accession Number:** 0000882796
**File Stem:** 0001140361-25-045599
**Filing Date:** 2025-12
**Character Count:** 2570
**Document Hash:** 837a8ecc5717988ab83802e57ccf17c8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-045599.hdr.sgml**: 20260609

**ACCESSION NUMBER**: 0001140361-25-045599

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOCRYST PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0000882796
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 621413174
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 4505 EMPEROR BOULEVARD
- **STREET 2:** SUITE 200
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703
- **BUSINESS PHONE:** 919-859-1302

**MAIL ADDRESS:**
- **STREET 1:** 4505 EMPEROR BOULEVARD
- **STREET 2:** SUITE 200
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703

------

December 16, 2025

![](ny20057110x4_img01.jpg)

#### VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Lauren Hamill

---

| | |
|:---|:---|
| **Re:** | **BioCryst Pharmaceuticals, Inc.** |
|  | **Amendment No. 1 to Registration Statement on Form S-4** |
|  | **Filed December 15, 2025** |
|  | **File No. 333-291678** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioCryst Pharmaceuticals, Inc. hereby requests that the effective date of its Registration Statement on Form S-4 (File No. 333-291678) be accelerated by the Securities and Exchange Commission to December 18, 2025 at 9:00 a.m., Eastern Time, or as soon as practicable thereafter.

Should you have any questions or comments regarding the foregoing, please contact Matthew T. Gehl of Covington & Burling LLP at (212) 841-1113. In addition, please notify Mr. Gehl by telephone when this request for acceleration has been granted.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| BIOCRYST PHARMACEUTICALS, INC. | BIOCRYST PHARMACEUTICALS, INC. |
| By: | /s/ Jon P. Stonehouse |
|  | Jon P. Stonehouse |
|  | Chief Executive Officer |

---

cc: Alane Barnes, BioCryst Pharmaceuticals, Inc.

Ben Harshbarger, Astria Therapeutics, Inc.

Jack S. Bodner, Covington & Burling LLP

Andrew W. Ment, Covington & Burling LLP

Matthew T. Gehl, Covington & Burling LLP

Charles A. Dobb, Covington & Burling LLP

Rosemary G. Reilly, Sidley Austin LLP

John H. Butler, Sidley Austin LLP

Sally Wagner Partin, Sidley Austin LLP

------